[Combined anti-EGFR and anti-HER2 monoclonal antibodies: preclinical efficacy in the treatment of pancreatic cancer]

Med Sci (Paris). 2007 Oct;23(10):800-3. doi: 10.1051/medsci/20072310800.
[Article in French]
No abstract available

Publication types

  • News

MeSH terms

  • Adenocarcinoma / immunology
  • Adenocarcinoma / therapy*
  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Dimerization
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / chemistry
  • ErbB Receptors / immunology
  • Humans
  • Immunotherapy*
  • Mice
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / immunology
  • Pancreatic Neoplasms / immunology
  • Pancreatic Neoplasms / therapy*
  • Panitumumab
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / chemistry
  • Receptor, ErbB-2 / immunology
  • Trastuzumab
  • Xenograft Model Antitumor Assays

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Neoplasm Proteins
  • Panitumumab
  • EGFR protein, human
  • ErbB Receptors
  • Receptor, ErbB-2
  • pertuzumab
  • matuzumab
  • Trastuzumab